When to Start Beta-Blockers in Chronic Liver Disease Patients
Non-selective beta-blockers (NSBBs) should be started in patients with chronic liver disease once clinically significant portal hypertension (CSPH) is confirmed or highly probable, defined by HVPG ≥10 mmHg or non-invasive criteria showing liver stiffness >20-25 kPa or the presence of any size varices on endoscopy. 1, 2
Risk Stratification Using Non-Invasive Criteria
The most recent guidelines emphasize a hemodynamic threshold-based approach rather than universal prophylaxis:
CSPH Excluded (Low Risk) - Do NOT Start NSBBs
- Liver stiffness measurement (LSM) <12 kPa AND platelets >150 G/L
- These patients can be discharged from CSPH surveillance
- If already on NSBBs/carvedilol, discontinuation can be considered 1
Probable CSPH (Intermediate Risk) - Perform Endoscopy
- LSM 20-25 kPa OR platelets <150 G/L
- Perform endoscopy if not already on NSBBs
- Start NSBBs if varices are present 1
Definite CSPH (High Risk) - Start NSBBs
- LSM >25 kPa (rules in CSPH)
- Any size gastroesophageal varices on endoscopy
- Spontaneous portosystemic collaterals
- NSBBs may be started without endoscopic proof of varices given high likelihood of CSPH 1, 3
Evidence-Based Rationale
The critical distinction is that NSBBs only work when CSPH is present. 2 Historic trials enrolling patients without confirmed CSPH showed no benefit and potential harm, while contemporary trials in hemodynamically defined CSPH cohorts demonstrate clear reduction in decompensation risk, particularly ascites 2, 4. The PREDESCI study established that treating all patients with CSPH prevents not just variceal bleeding but all forms of decompensation 1.
Specific Clinical Scenarios
Compensated Cirrhosis with Medium/Large Varices
Start NSBBs immediately for primary prophylaxis. This reduces first variceal hemorrhage from 30% to 14%, preventing one bleeding episode for every 10 patients treated 5, 6.
Small Varices with High-Risk Features
Start NSBBs if Child-Pugh B/C or red wale marks present on varices 6. Without these features, NSBBs can be used but long-term benefit is less established 6.
Post-Etiological Treatment (e.g., HCV cure)
If CSPH persists after viral cure or other etiological treatment (evidenced by varices or LSM >20 kPa), continue or initiate NSBBs. These patients still benefit with 16% vs 44% decompensation rates on vs off NSBBs 4.
History of Variceal Bleeding (Secondary Prophylaxis)
Continue NSBBs plus endoscopic band ligation indefinitely unless post-treatment LSM decreases to <12 kPa AND platelets >150 G/L 1, 6.
Drug Selection and Dosing
Carvedilol is preferred as it combines β-blockade with α1-adrenergic vasodilator activity, providing both splanchnic vasoconstriction and intrahepatic vasodilation 5. Alternative NSBBs include propranolol or nadolol.
- Start nadolol 40 mg once daily or propranolol 20 mg twice daily
- Titrate to maximum tolerated dose or heart rate reduction of 25% from baseline
- Target HVPG reduction to <12 mmHg or ≥20% from baseline (if measured) 6
Critical Contraindications and Cautions
Hold or discontinue NSBBs in:
- Refractory ascites with systolic blood pressure <90 mmHg 7
- Severe symptomatic hyponatremia (sodium <120 mEq/L) with hypotension 7
- Spontaneous bacterial peritonitis or hepatorenal syndrome (controversial - requires individualized assessment)
For patients unable to take NSBBs due to contraindications or intolerance, endoscopic band ligation is the alternative for high-risk varices 8, 6.
Common Pitfalls to Avoid
- Do not start NSBBs in all compensated cirrhosis patients - they only work with CSPH present and may cause harm in earlier stages 2
- Do not use selective β-blockers (atenolol, metoprolol) - they are suboptimal as they lack the critical β2-blocking effect needed for splanchnic vasoconstriction 5, 6
- Do not stop NSBBs after variceal obliteration - the portal hypertension persists and bleeding risk recurs when stopped 6
- Do not rely solely on absence of varices - CSPH can exist without varices, and preventing all decompensation (not just bleeding) is the goal 1
The shift from endoscopy-based to hemodynamic-based initiation of NSBBs represents a paradigm change, with screening for CSPH rather than just varices becoming the diagnostic priority 1.